Discovery, Inc. Overview
Discovery Limited is a South African-founded financial services group whose defining asset is the Vitality Shared-Value insurance model — a behavioural-economics engine that rewards customers for healthier living, safer driving and better financial habits, and converts those behaviours into lower claims, better persistency and higher lifetime value. In South Africa it operates a vertically integrated ecosystem spanning health-insurance administration (the country's largest open medical scheme, Discovery Health Medical Scheme), life assurance, investments, short-term insurance and a digital bank that turned its first full-year profit in FY2026 and is now being repositioned as a "Super Bank" orchestration layer. Internationally, the Vitality composite owns VitalityHealth and VitalityLife in the UK, holds an equity stake in Ping An Health Insurance in China, and licenses Vitality to tier-one insurers such as AIA, Sumitomo Life, John Hancock and Manulife. FY2026 normalised operating profit reached ZAR 17.75 billion with a normalised ROE of 16.5%, positioning Discovery as one of Africa's most valuable insurers by market value.
Company's own description
Discovery describes itself as a South African-founded financial services organisation operating in healthcare, life assurance, short-term insurance, banking, savings and investment, and wellness markets, guided since 1992 by a core purpose of making people healthier and enhancing and protecting their lives. It states that the Vitality model is active in 36 countries with over 50 million members, exported through the Global Vitality Network of large insurer partners, including AIA (Asia), Ping An (China), Sumitomo (Japan), John Hancock (US), Manulife (Canada) and its wholly owned Vitality Life & Health business in the UK [S1].
Profile's Stock Exchange Handbook (2026 Issue 2) characterises Discovery as a diversified financial services organisation operating in health insurance, life insurance, long-term savings and investments, short-term and commercial insurance, banking and behaviour-change programmes [S29].
Operating architecture (FY2026)
Since FY2025 Discovery has run the group as two composites [S13]:
-
Discovery South Africa (Discovery SA) — Discovery Health (medical scheme administration and managed care), Discovery Life, Discovery Invest, Discovery Insure, Discovery Bank, Discovery Vitality (SA), plus Discovery Corporate & Employee Benefits and smaller initiatives such as Discovery Green.
-
Vitality (global composite) — VitalityHealth UK, VitalityLife UK, Vitality Global Markets (Vitality Network partner fees, Vitality Health International "other", Vitality USA/Vitality Group), the equity-accounted share of Ping An Health Insurance (PAHI), and Vitality AI. In FY2026 the composite completed a regionalised operating model with the UK as centre of excellence [S1].
Revenue model
| Revenue model | Where it sits | Characterisation |
|---|---|---|
| Administration and managed-care fees (service) | Discovery Health (fees from DHMS and closed schemes) | Capital-light, annuity-like, high cash conversion |
| Risk premiums (insurance) | Discovery Life, Discovery Insure, VitalityHealth UK, VitalityLife UK | Underwriting margin plus Vitality-driven claims advantage |
| Asset-based fees (savings) | Discovery Invest | Tied to AUM and net inflows |
| Net interest income and transaction fees (banking) | Discovery Bank | Scaling; ZAR 3.1 billion revenue in FY2026 [S1] |
| Licensing / partner fees (IP licensing) | Vitality Network, Vitality Group (US) | Capital-light, USD-linked |
| Equity-accounted earnings | Ping An Health Insurance (China); associates such as CMT | Share of after-tax operating profit |
Discovery does not publish a conventional consolidated "revenue" line as its headline metric; under IFRS 17, insurance revenue, fee income, net interest income and investment income are presented separately, and management steers by normalised operating profit and new business annualised premium income (API) [S5], [S12]. The mix by economic model:
Value-chain position, customers and end markets
Discovery operates as product manufacturer, administrator and distributor (through a large tied and independent adviser force), and increasingly as a digital platform owner (the Discovery and Discovery Bank apps). Customer types: affluent and upper-middle-income retail clients in South Africa (Discovery SA served 6.4 million clients in FY2025, up 6% [S14]); corporate employers (group risk, retirement funds, employer health); UK retail and SME customers (VitalityHealth and VitalityLife, over two million UK customers in FY2025 [S13]); global insurers (Vitality Network licensees); and US health plans and employers (Vitality USA, now augmented by Icario) [S23].
Independent characterisation. Discovery is best understood as a behavioural-data platform monetised through regulated balance sheets. Its moat is the joint ownership of the client across health, life, short-term insurance, investments and banking, which lets Vitality status reduce risk in every product while the bank captures the daily engagement data. The key strategic question for the next five years is whether the bank-centred "Super Bank" orchestration can lift multi-product penetration among Discovery SA clients (management notes that roughly 75% of Discovery members are not yet bank clients [S7]) while the international Vitality franchise scales capital-light.
Strategy
Stated strategy
- Five-year strategy (FY2025–FY2029), "scaled organic growth" phase. FY2026 is described as two years into this plan [S2]. The ambition is to compound normalised profit at 15%–20% per year through 2029 — roughly doubling the business — while reducing spend on new initiatives as they mature [S11]. Management indicated in FY2026 that it is tracking toward the middle-to-upper end of that ambition [S2].
Two composites defined by distinct value drivers: Discovery SA (integrated ecosystem) and Vitality (global, capital-light shared-value platform) [S2], [S13].
Super Bank strategy (South Africa): Discovery Bank evolves into an integrated platform orchestrating clients' banking, health, insurance and investments, with AI-driven personalisation; second phase launch scheduled for 1 October 2026 [S1], [S8].
- Vitality Shared-Value model scaled globally, with commercialisation/monetisation of Vitality AI and capital-light, high-return international initiatives [S2].
Financial discipline: lower financial leverage (15.4% in FY2026), higher cash conversion, progressive dividend [S7].
Initiatives in the last 24 months
| Initiative | Date | Description / target | Source |
|---|---|---|---|
| Discovery AI (bank) | FY2025 | AI assistant in Discovery Bank | [S13] |
| Vitality AI / Personal Health Pathways | FY2025 | AI-personalised health pathways in Discovery SA | [S13] |
| Discovery Bank profit target | Sep 2026 | ZAR 3 billion annual profit and ~2 million clients by FY2029; revenue growth 15%–20% per year | [S8], [S11] |
| Super Bank phase 2 | 1 Oct 2026 | AI-connected group offerings through the bank | [S8] |
| Head-office ownership | Feb 2026 | Switch from lease to ownership, ~ZAR 800 million NPV benefit | [S21] |
| Vitality regional operating model | FY2026 | UK as centre of excellence; costs apportioned across composite | [S1] |
| US expansion (Icario) | Sep 2026 | Government-sponsored health-plan market | [S1], [S23] |
| Personal loans, Luno crypto, Discovery Pay | 2025–2026 | Bank product extensions | site |
| Sleep Rewards / Oura Ring | 2025–2026 | New Vitality behaviours rewarded | site, [S1] |
| Net-zero transition plan | FY2025 | Net zero by 2050 or earlier | [S35] |
Medium-term targets and guidance
-
Normalised profit growth of 15%–20% per year to FY2029 [S11].
-
Discovery Bank: ZAR 3 billion profit by FY2029 [S8].
-
Dividend: FY2026 cover of 4.5x; FY2025 policy referenced a 35% payout ratio (previously 30%) [S2], [S12].
-
No formal numerical guidance for FY2027 was identified in sources retrieved.
Products & Services
Pricing models are product-specific premiums/fees; detailed price lists are published only for some retail products and are noted where retrieved.
Discovery Health / Discovery Health Medical Scheme (South Africa)
| Offering | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| Discovery Health Medical Scheme (DHMS) plans | Open medical scheme administered by Discovery Health; plan series (Executive, Comprehensive, Priority, Saver, Core, Smart, KeyCare — series names per company materials, not re-verified) | Individuals, families, employer groups | DHMS reported a 17.7% lower cost per benefit unit vs competitors (FY2026) [S1] |
| WELLTH Fund cover | Preventive screening and wellness benefit within DHMS | DHMS members | 2026 benefit structure [S24 site] |
| Personal Health Pathways (PHP) | Vitality AI-driven personalised health pathway (Vitality AI launched as PHP in FY2025) | DHMS/Vitality members | [S13] |
| Gap Cover | Covers shortfalls between provider charges and scheme rates | Medical-scheme members | Promotional offer: start paying from month four (2026) [site] |
| Emergency (trauma) Cover | Standalone emergency cover | Uninsured/underinsured | [site] |
| Supplementary Illness Benefit | Top-up cover for illness events | Scheme members | [site] |
| Prepaid Health | Prepaid primary-care product | Lower-income market | [site] |
| Flexicare (incl. Flexi Fund Benefit) | Primary-care health insurance (non-scheme) | Entry-level market | 2026 benefits and premiums published [site] |
| Discovery Health app / single primary-care GP nomination / chronic illness benefit | Digital and managed-care capabilities | Members | [site] |
| Closed-scheme administration and managed care | Administration services for restricted (employer) schemes | Corporates | Non-medical-scheme products were 15% of Discovery Health revenue in FY2024 [S16] |
Discovery Life
| Offering | Description | Target customer |
|---|---|---|
| Life cover / Purple Life Plan | Bespoke integrated life, disability and severe-illness cover; Vitality-linked premium discounts and paybacks | Affluent and high-net-worth retail |
| Dollar Life Plan | Life cover denominated in US dollars | Clients seeking hard-currency protection |
| Global Education Protector | Education funding protection | Parents |
| Funeral cover | Funeral plans | Mass/middle market |
| Discovery Life Business Insurance | Key-person, buy-and-sell and business-assurance cover | Business owners |
| Personalised PayBack Booster | Reward enhancement linked to engagement (new) | Life clients |
| Wills and estate planning | Free will service | Life clients |
| Group Risk (via Corporate & Employee Benefits) | Group life and disability | Employers |
Discovery Life held a 27% share of the affluent retail protection market in FY2026 [S1]. Engaged (Gold/Diamond Vitality) Life clients are reported to gain an average of six additional years of life versus non-engaged members [S1].
Discovery Invest
| Offering | Description |
|---|---|
| Retirement annuities ("Retire Strong") | Boost of up to 20% for staying invested (adviser-sold) |
| Fixed annuities; Secured Capital Annuity; Lifespan Linked Income Plan | Retirement income solutions |
| Retirement savings and income plans | Living-annuity style products |
| Global endowments (lump-sum and recurring) and global flexible investment plan | Offshore investment wrappers |
| Flexible investment plans, endowment plans, guaranteed return plans | Discretionary investments |
| Discovery funds and external fund platform | Unit trusts / third-party funds |
| Shared-value investing | Vitality-linked investment rewards (ZAR 20 billion shared-value milestone referenced on site) |
AUM: ZAR 155 billion at FY2024 (+11%) [S18]; FY2026 AUM not publicly disclosed in sources retrieved; FY2026 operating profit growth was supported by strong asset growth and positive net inflows [S1].
Discovery Insure (short-term insurance)
| Offering | Description |
|---|---|
| Car insurance (plans incl. Vitality Drive) | Telematics-based personal motor cover; PerfectDrive rewards up to Discovery Miles 100 per qualifying trip day (Bank-linked) |
| Home insurance: buildings, household contents, portable possessions | Personal lines |
| Vehicle warranty cover | Ancillary |
| Discovery 911 safety devices | Smoke detector, panic button, virtual panic button |
| Vitality Drive rewards | Fuel cash-back (Shell partnership), safety features |
| Commercial insurance | Business lines (scope not detailed in sources retrieved) |
Engaged Insure clients have 74% lower road fatality rates (FY2026) [S1].
Discovery Bank
| Product family | Named offerings |
|---|---|
| Credit cards and suites | Credit card collection; full banking suites |
| Lending | Home loans (book above ZAR 4 billion in FY2026, +129%); revolving credit facility; personal loans (newly launched) |
| Transaction and savings | Bundled and pay-as-you-transact accounts; real-time forex accounts; savings accounts |
| Investments and digital assets | EasyEquities trading integration; crypto trading via Luno (new) |
| Payments and digital | Discovery Bank app; Discovery Pay; Discovery AI; Vitality Money Financial Analyser |
| Rewards | Vitality Money; Discovery Miles and Discovery Miles+ network; Vitality Travel; Priority Fast Track; The Lounge by Discovery and SAA |
FY2026 metrics: 1.57 million clients (+26%), revenue ZAR 3.1 billion (+31%), retail deposits ZAR 27.2 billion (+17%), gross retail advances ZAR 12.9 billion (+40%), about 3.8 million accounts; 70% of new business originated outside the Discovery Group; 73% of new home loans to super-prime clients [S1], [S8], [S9].
Discovery Vitality (South Africa)
Vitality Active Rewards, Vitality Sleep Rewards (incl. smartphone sleep tracker and Oura Ring offer), Vitality HealthyFood, Vitality Fitness/gym, Vitality Travel rewards, Vitality 65+, family/teen programmes, device partnerships (e.g. Apple Watch imagery in FY2026 media kit), Healthy Food Studio, Team Vitality running/cycling club [site], [S1].
Discovery Corporate & Employee Benefits
Group risk, retirement funds and employer health solutions; unit created 1 January 2024 under CEO Nonkululeko Pitje [S26].
Vitality UK
VitalityHealth: private medical insurance (individual and corporate), with Vitality engagement programme. FY2026 operating profit GBP 83.6 million [S1].
VitalityLife: life, serious-illness and income protection cover; FY2026 operating profit GBP 34.5 million, new business +25% [S1].
Vitality Global
Vitality Network: licensing of the Vitality programme to insurers (AIA, Ping An, Sumitomo Life, John Hancock, Manulife and others) [S1].
Vitality USA / Vitality Group: employer and health-plan engagement; expanded with Icario (health-action/member-activation platform for Medicare, Medicaid and commercial plans). Combined entity: ~19 million members and ~30% of US health plans, including eight of the ten largest [S23].
Vitality AI: global AI-driven personalisation layer; FY2026 net cost ZAR 299 million (incl. other central costs) [S2]; FY2026 media kit references a Google collaboration on Vitality AI (scope not detailed in sources retrieved) [S1].
Ping An Health Insurance (PAHI): equity-accounted Chinese health insurer; 35.4 million insured lives (+10%) in FY2026 [S1].
Financial Narrative
Income statement and per-share data (ZAR)
Sources: FY2022 (IFRS 4) from FY2023 trading statement and Daily Investor [S19]; FY2023 (IFRS 17 restated) and FY2024 from FY2024 results [S16]; FY2024 HE/NHE restated per FY2025 SENS [S12]; FY2025 [S12], [S13], [S14]; FY2026 [S1], [S3], [S4], [S5]. Dividends: FY2023 final 110c only [S19]; FY2024 interim 65c + final 152c [S20], [S16]; FY2025 interim 87c + final 201c [S20], [S12]; FY2026 interim 111c + final 273c = 384c [S20], [S6]. FY2022 headline earnings and normalised headline earnings (IFRS 4) are not shown because only per-share figures were retrieved; under IFRS 4 as originally reported, FY2023 HE was ZAR 5.49 billion and NHE ZAR 7.68 billion [S19]. FY2024 per-share figures are as originally reported (not restated).
Metrics not applicable / not disclosed: Revenue, gross profit, gross margin, EBITDA and EBITDA margin are not reported by Discovery as performance measures and are not meaningful for a composite insurer–bank. A secondary aggregator lists FY2025 revenue of ZAR 37.03 billion and net income of ZAR 9.55 billion [S34]. Interim H1 FY2026 attributable income was ZAR 5,716 million (H1 FY2025: ZAR 4,285 million) [S28 ShareData].
Returns, capital and quality-of-earnings metrics
Sources: ROE [S12], [S1]; cash conversion FY2023 64% and FY2024 66% originally, restated 65% [S16], [S12]; FY2025 77% [S12]; FY2026 85% [S7]; embedded value and RoEV [S1], [S10]; leverage [S7]; dividend cover FY2025 "five times" [S13] and FY2026 4.5x [S2]. Note: the FY2025 SENS also references a 35% payout ratio (previously 30%), which is not arithmetically identical to a 5x cover on normalised HEPS; both figures are reported and the discrepancy likely reflects different earnings bases.
Interim H1 FY2026: normalised operating profit +24%; normalised ROE 17.4% (annualised); Discovery SA +19%; Vitality +41%; cash conversion 71% (H1 FY2025: 76%) [S20].
Balance sheet
Cash and equivalents, total debt split (short/long term), net debt, goodwill and intangibles: not publicly disclosed in the sources retrieved. Known debt events: the ZAR 4.05 billion 1 Discovery Place purchase was fully funded via pre-arranged debt (FY2026); management states leverage excluding 1DP debt is being reduced and finance costs fell in FY2026 [S21], [S4], [S2]. Working capital and current ratio are not applicable to an insurer/bank balance sheet.
Cash flow
Operating cash flow, capex, free cash flow and buybacks: not publicly disclosed in sources retrieved. Disclosed proxies: cash conversion of 85% of after-tax normalised operating profit in FY2026 [S7]; dividends declared of 384 cents per share for FY2026, equivalent to roughly ZAR 2.6 billion on ~669 million shares (derived). No share buyback programme was identified in sources retrieved.
Commentary on trends, inflections and drivers
FY2022–FY2023 (recovery). Normalised operating profit rose 24% under IFRS 4 in FY2023 as Covid-19 claims normalised, Group Life returned to profit and the cost of new initiatives fell; dividends resumed at 110 cents after a pandemic suspension [S19]. Headline earnings were depressed relative to normalised earnings by the impact of sharply higher South African real and nominal interest rates on insurance liabilities, which Discovery normalises out [S19].
FY2024 (IFRS 17 transition, UK setback). Normalised operating profit grew 17% to ZAR 11.6 billion, but the UK health business absorbed a GBP 30 million claims shock as claims inflation outran lagged premium increases, cutting VitalityHealth operating profit by 52% [S16]. Discovery Bank's loss narrowed 41% to ZAR 454 million [S16].
FY2025 (inflection). Normalised operating profit jumped 29% to ZAR 15.2 billion, with Discovery SA +22% and Vitality +70% as the UK repriced and PAHI delivered; normalised ROE reached 15.4% [S13]. Discovery Insure's profit more than tripled [S15].
FY2026 (maturity and de-gearing). Growth moderated to a still-strong 17% at operating level, but normalised headline earnings grew faster (+21%) because finance costs fell with planned deleveraging [S1], [S4]. Reported headline earnings (+34%) were flattered by a one-off gain on terminating the 1 Discovery Place lease [S4]. The quality of earnings improved: cash conversion rose to 85% and the bank turned profitable [S7]. A softer spot is embedded-value return, which declined to 14.1% from 15.7% [S10], and total new business API growth of only 6% [S1].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Discovery South Africa normalised operating profit (ZAR Mn) | 9,717 | 12,005 | 13,868 |
Vitality composite normalised operating profit (ZAR Mn) | — | 3,205 | 3,882 |
Group normalised profit from operations (ZAR Mn) | 11,604 | 15,210 | 17,750 |
Composite share of group normalised operating profit (%)
| Composite share of group normalised operating profit (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Discovery South Africa (%) | 83.7 | 78.9 | 78.1 |
Vitality / international (%) | 16.3 | 21.1 | 21.9 |
Revenue by Segment
| Business | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Discovery Health (ZAR Mn) | 3,972 | 4,250 | 4,630 |
Discovery Life (ZAR Mn) | — | 5,525 | 5,872 |
Discovery Invest (ZAR Mn) | 1,500 | 1,987 | 2,157 |
Discovery Insure incl. associates (ZAR Mn) | 248 | 817 | 1,010 |
Discovery Bank (ZAR Mn) | -454 | -68 | 370 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFY2026 YoY growth and contribution
| FY2026 YoY growth and contribution | Growth (%) | Share of group normalised operating profit (%) |
|---|---|---|
Discovery Health | 9 | 26.1 |
Discovery Life | 6 | 33.1 |
Discovery Invest | 9 | 12.2 |
Discovery Insure | 24 | 5.7 |
Discovery Bank |
| 2.1 |
Vitality composite | 21 | 21.9 |
Results by Segment and Revenue by Segment
| Vitality business | FY2025 | FY2026 | FY2026 growth (%) |
|---|---|---|---|
VitalityHealth UK operating profit (GBP Mn) | — | 83.6 | 65 |
VitalityLife UK operating profit (GBP Mn) | — | 34.5 | 27 |
VitalityLife UK operating profit (ZAR Mn) | — | 782 | 23 |
Ping An Health Insurance — Discovery share of after-tax operating profit (ZAR Mn) | 1,206 | 1,317 | 9 |
Vitality Global Markets (Vitality Network + VHI other) (ZAR Mn) | — | 186 | -29 |
Vitality AI and other central Vitality costs (ZAR Mn) | — | -299 | — |
Key Financials and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Normalised profit from operations (ZAR Mn) | 9,380 | 9,917 | 11,604 | 15,210 | 17,750 |
Headline earnings (ZAR Mn) | — | 6,720 | 7,384 | 9,625 | 12,923 |
Normalised headline earnings (ZAR Mn) | — | 6,400 | 7,511 | 9,781 | 11,795 |
Basic EPS (ZAR cents) | 825.5 | — | — | 1,402.2 | 1,936.7 |
Diluted EPS (ZAR cents) | — | — | — | — | 1,926 |
Basic HEPS (ZAR cents) | 792.4 | 1,021.5 | 1,089.4 | 1,447.0 | 1,925.6 |
Basic normalised HEPS (ZAR cents) | 885.5 | 972.8 | 1,108.6 | 1,470.4 | 1,757.6 |
Dividend per share, full year (ZAR cents) | 0 | 110 | 217 | 288 | 384 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Normalised operating profit CAGR FY2023–FY2026 | 21.4% | IFRS 17 consistent, derived |
Normalised operating profit CAGR FY2022–FY2026 | 17.3% | Mixed IFRS 4/IFRS 17 basis — indicative only |
Normalised headline earnings CAGR FY2023–FY2026 | 22.6% | IFRS 17 consistent, derived |
Dividend per share CAGR FY2023–FY2026 | 51.7% | Reflects dividend resumption off a low base |
FY2026 normalised operating profit growth | 17% | [S1] |
FY2026 headline earnings growth | 34% (boosted by gain on termination of 1DP lease) | [S1], [S4] |
FY2026 normalised headline earnings growth | 21% | [S1] |
Share price | ZAR 261.31 | MarketScreener, 28 Sep 2026 [S28] |
YTD change | +14.82% | [S28] |
52-week range | ZAR 193.29 – 291.17 | [S28] |
3-year range | ZAR 107.12 – 291.17 | [S28] |
5-year range | ZAR 100.73 – 291.17 | [S28] |
Approx. 1-year change to Feb 2026 | ZAR 191.23 → 233.18 (+22%) | [S21] |
Market cap | ~ZAR 176 billion | [S28] |
Enterprise value | ~ZAR 195 billion | [S28] |
Trailing P/E on normalised HEPS (FY2026) | ~14.9x | Derived (261.31 / 17.576) |
Trailing P/E on HEPS (FY2026) | ~13.6x | Derived |
Forward P/E FY2027 / FY2028 (consensus) | 13.2x / 11.8x | [S28] |
EV/Sales FY2027 / FY2028 (consensus) | 2.2x / 2.12x | [S28] |
Trailing dividend yield | ~1.5% (384c / ZAR 261.31) | Derived |
Price/book | Not publicly disclosed in sources retrieved | — |
Analyst coverage | 15–18 analysts | [S29] |
Consensus target (snapshot) | ~ZAR 257–293 at different dates; range ZAR 207.10–284.78 | Simply Wall St [S28] — dated, indicative only |
Margin Analysis (%) and Key Financials
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Normalised return on equity (%) | — | 13.5 | 15.4 | 16.5 |
Cash conversion, after-tax normalised operating profit (%) | 64 | 65 | 77 | 85 |
Return on embedded value (%) | — | — | 15.7 | 14.1 |
Group embedded value (ZAR Bn) | — | — | — | 143 |
Financial leverage (%) | — | — | — | 15.4 |
Dividend cover (times) | — | — | 5.0 | 4.5 |
Balance Sheet
| Metric | FY2025 | FY2026 |
|---|---|---|
Total assets (ZAR Bn) | 327.45 | — |
Total equity (ZAR Bn) | 65.69 | — |
Discovery Bank retail deposits (ZAR Bn) | 23.3 | 27.2 |
Discovery Bank gross retail advances (ZAR Bn) | 9.2 | 12.9 |
Discovery Bank net loans and advances (ZAR Bn) | 8.5 | 13.0 |
Returns & Leverage Ratios (%)
| Ratio | FY2026 value | Comment |
|---|---|---|
ROE (normalised) | 16.5% | Up from 15.4% [S1] |
ROIC | Not applicable / not disclosed | Insurer |
Debt/equity | Not publicly disclosed; financial leverage 15.4% | [S7] |
Revenue by Region
| Geography (normalised operating profit, ZAR Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
South Africa (Discovery SA composite) (ZAR Mn) | 9,717 | 12,005 | 13,868 |
International (UK, China share, global network, US) (ZAR Mn) | 1,887 | 3,205 | 3,882 |
Geography growth (%)
| Geography growth (%) | FY2025 | FY2026 |
|---|---|---|
South Africa (%) | 22 | 16 |
International / Vitality (%) | 70 | 21 |
Per-Share Data
| Price reference (ZAR) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Full-year DPS (ZAR cents) | 217 | 288 | 384 |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
Moody's (global scale, long-term issuer) | Ba3 | Stable | Affirmed 18 Nov 2024 |
Moody's (national scale) | Aa3.za (upgraded from A1.za) | Stable | 18 Nov 2024 |
Analyst Conclusions
Management guidance
-
Normalised profit growth of 15%–20% per year to FY2029, with management indicating progress toward the middle-to-upper end [S2], [S11].
-
Discovery Bank: ZAR 3 billion profit and about 2 million clients by FY2029; revenue growth 15%–20% a year [S8], [S11].
-
Continued deleveraging and high cash conversion [S7].
Bull case
-
Bank operating leverage: a move from ZAR 370 million to ZAR 3 billion profit by FY2029 would add more than ZAR 2.6 billion to annual operating profit — about 15% of the FY2026 group base [S1], [S8].
-
Capital-light Vitality growth: UK health profit +65%, PAHI +9% and the Icario-enabled US push support a rising international share [S1], [S23].
-
Quality of earnings: cash conversion of 85%, leverage of 15.4% and a fast-growing dividend give room for re-rating against peers [S7], [S6].
Bear case
-
Growth deceleration: total new business API grew only 6% and RoEV declined to 14.1%, signalling that profit growth may outpace value creation [S1], [S10].
-
Policy risk: the NHI Act threatens the long-term scope of medical schemes, Discovery's anchor business [S33].
-
Valuation already discounts success: at ~14.9x trailing normalised earnings versus Momentum's lower earnings base but higher ROE (21.7%), Discovery offers less ROE per multiple turn [S28], [S31].
Catalysts and monitorables (next 12 months)
-
Uptake metrics from Super Bank phase 2 (launched 1 Oct 2026).
-
Interim H1 FY2027 results (expected ~March 2027): bank profit run-rate; Vitality UK claims ratio.
-
Icario integration and US health-plan contract wins.
-
NHI litigation and CMS regulatory decisions.
-
Any credit-rating action and capital deployment (dividends vs. M&A).
-
Competitive response in health administration post Momentum–Bonitas.
Analyst verdict
Discovery enters FY2027 in the strongest financial position of its post-pandemic history. The two-composite reorganisation has produced a cleaner story: a mature, cash-generative South African franchise growing in the mid-teens, and an international Vitality composite growing faster off a lower base. FY2026 delivered on almost every metric management controls — normalised operating profit +17%, normalised headline earnings +21%, ROE 16.5%, cash conversion 85%, leverage down to 15.4% — and, most symbolically, Discovery Bank's first full-year profit after an estimated ZAR 15 billion of investment.
The investment case now hinges on two execution questions. First, can the Super Bank turn Discovery's broad but shallow client relationships into deeper, bank-anchored ones? The ZAR 3 billion FY2029 bank target is ambitious and implies near-eightfold profit growth; credit quality on a book growing 40% a year must be watched closely, though the super-prime skew is reassuring. Second, can Vitality convert scientific credibility into scalable, capital-light revenue outside the UK and China? The −29% result in Vitality Global Markets and the cost of Vitality AI show that this leg is still in investment mode, and Icario is a meaningful bet on the US government-sponsored market.
Risks are real but mostly slow-moving. NHI remains the largest long-dated threat to the health franchise, and slower new business API growth and a lower RoEV suggest that reported profit growth is outpacing underlying value growth. At roughly 13–15x earnings with a ~1.5% yield, the market already prices in delivery of the 15%+ growth corridor. On balance, Discovery screens as a high-quality compounder with execution-dependent upside: fairly valued on current guidance, with upside if the bank and Vitality AI outperform and downside if new business momentum continues to fade. This verdict is analytical, not investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / since | Prior roles and background | Source |
|---|---|---|---|---|
Adrian Gore | Founder, Executive Director and Group Chief Executive | Since 1992 | Founded Discovery; awards include EY Best Entrepreneur (1998), Sunday Times Business Leader of the Year (2010), EY Global Lifetime Achiever (2017); author of The Four Principles | [S24], [S6] |
Deon Viljoen | Executive Director, Group CFO | Since 1 May 2017 | Alexander Forbes (joined 2003; Group CFO from 2007; interim CEO 2016); former Partner, PwC Johannesburg; CFO SA CFO of the Year 2015 | [S24] |
Barry Swartzberg | Executive Director, CEO: Vitality Group | Co-founder (1992) | Discovery Health CMO 1992–96, COO 1997–99, CEO 2000–05; Group Executive Director, strategy 2005–14 (initiated bank strategy, Discovery Insure, PAHI stake, AIA partnership, Vitality USA) | [S24] |
Hylton Kallner | CEO, Discovery Bank; CEO, Discovery SA composite (from 1 Mar 2023) | Bank CEO since inception | Stepped down from Discovery Limited board effective 1 Mar 2023 | [S26], [S11] |
Dr Ronald Whelan | CEO, Discovery Health | Since 1 Jan 2024 | Joined Discovery Health 2019; former Deputy CEO; led Covid-19 vaccination collaboration | [S26] |
Nonkululeko Pitje | CEO, Discovery Corporate & Employee Benefits | Since 1 Jan 2024 | Joined Discovery 2004; former Chief Growth Officer, Discovery Health | [S26] |
Maia Surmava | CEO, Vitality U.S. | — | — | [S23] |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Independence | Background highlights |
|---|---|---|---|
Mark Tucker | Chairperson (appointed 1 Mar 2019) | Independent non-executive | Former Group CEO, AIA Group; former Group CEO, Prudential plc; former Group Chair, HSBC Holdings; former NED Goldman Sachs Group; Court of the Bank of England 2009–12 |
Adrian Gore | Group Chief Executive | Executive | Founder |
Deon Viljoen | Group CFO | Executive | See above |
Barry Swartzberg | CEO: Vitality Group | Executive | Co-founder |
Monhla Hlahla | Director | Independent non-executive | Former MD, Airports Company South Africa; former Chair, IDC |
Bridget van Kralingen | Director | Independent non-executive | Former SVP, IBM Global Markets; technology and AI expertise |
Faith Khanyile | Director | Independent non-executive | Founding CEO, WDB Investment Holdings; ex-Standard Bank CIB |
Richard Farber | Director | Non-executive (not independent; former CFO) | Discovery CFO 2003–2017 |
Marquerithe Schreuder | Director | Independent non-executive | Actuary; former INED, Hannover Re Africa |
David Macready | Director | Independent non-executive | Former CEO, Old Mutual South Africa; ex-Nedbank Wealth |
Lisa Chiume | Director (since Sep 2023) | Independent non-executive | Ex-Deutsche Bank SA, ex-RMI/RMH; Executive Director, Alphacode |
Christine Ramon | Director (since Sep 2023) | Independent non-executive | Former CFO, AngloGold Ashanti and Sasol |
Nolitha Fakude | Director (since 27 Aug 2025) | Independent non-executive | Board experience incl. Sasol, Woolworths, JSE and Discovery Bank Holdings |
Major Shareholders
| Rank | Holder | Stake (%) | Source / date |
|---|---|---|---|
| 1 | Public Investment Corporation (SOC) Ltd | 13.5 | Simply Wall St (2026 data) [S29] |
| 2 | Remgro Limited | 7.69 | [S29] |
| 3 | Adrian Gore (direct and indirect) | 6.71 to 6.83 | Profile's Handbook 2026 (14 Apr 2026): 6.71% [S29] |
| 4 | Royal Bank of Canada (banking & securities investments) | 5.09 | [S29] |
| 5 | Capital Research and Management Company | 5.06 | [S29] |
| 6 | Baillie Gifford & Co. | 4.9 (7.50 in Sep 2023) | [S29] |
| 7 | The Vanguard Group | 3.46 | [S29] |
| 8 | RBC Global Asset Management | 3.3 | [S29] |
| 9 | Barry Swartzberg | 3.29 | [S29] |
| 10 | Ninety One UK / Sanlam Investment Mgmt / Old Mutual Investment Group / Norges Bank (stakes not disclosed in source) | — | [S29] |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors |
|---|---|
Health administration / medical schemes (SA) | Momentum Health (now also administering Bonitas), Medscheme/AfroCentric, Government Employees Medical Scheme (restricted), Bestmed, Medshield, Fedhealth |
Life protection (SA) | Sanlam, Old Mutual, Momentum (incl. Momentum Retail, Metropolitan), Liberty (Standard Bank group), BrightRock, Assupol (now Sanlam) |
Investments (SA) | Allan Gray, Coronation, Ninety One, Sanlam/Glacier, Old Mutual Wealth, Momentum Investments, 10X |
Short-term insurance (SA) | OUTsurance, Santam, Hollard, Momentum Insure, King Price, MiWay (Old Mutual) |
Retail banking (SA) | Capitec, FNB (FirstRand), Standard Bank, Absa, Nedbank, Investec, TymeBank |
UK private medical insurance | Bupa, AXA Health, Aviva |
UK protection | Legal & General, Aviva, Royal London, Zurich, LV= |
Global wellness/engagement (US) | Virgin Pulse/Personify Health, other health-plan engagement vendors |
Peer Comparison FY2026
| Metric | Discovery (FY Jun-2026) | Momentum Group (FY Jun-2026) | Sanlam (FY Dec-2025) |
|---|---|---|---|
Core earnings measure (ZAR Mn) | 11795 (NHE) | 7060 (NHE) | 15939 (NRFFS) |
Growth in core earnings (%) | 21 | 13 | 3 (20 normalised) |
Operating profit (ZAR Mn) | 17750 (normalised profit from operations) | 5970 (operating profit) | — |
ROE (%) | 16.5 | 21.7 | — |
Full-year DPS (ZAR cents) | 384 | 230 | — |
DPS growth (%) | 33 | 31 | 9 |
